CA2382817C - Use of fibrin or fibrinogen for reducing lung tissue volume - Google Patents
Use of fibrin or fibrinogen for reducing lung tissue volume Download PDFInfo
- Publication number
- CA2382817C CA2382817C CA2382817A CA2382817A CA2382817C CA 2382817 C CA2382817 C CA 2382817C CA 2382817 A CA2382817 A CA 2382817A CA 2382817 A CA2382817 A CA 2382817A CA 2382817 C CA2382817 C CA 2382817C
- Authority
- CA
- Canada
- Prior art keywords
- lung
- fibrinogen
- fibrin
- region
- growth factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000004072 lung Anatomy 0.000 title claims abstract description 197
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 title claims abstract description 128
- 229940012952 fibrinogen Drugs 0.000 title claims abstract description 121
- 108010049003 Fibrinogen Proteins 0.000 title claims abstract description 120
- 102000008946 Fibrinogen Human genes 0.000 title claims abstract description 120
- 108010073385 Fibrin Proteins 0.000 title claims abstract description 105
- 102000009123 Fibrin Human genes 0.000 title claims abstract description 105
- 229950003499 fibrin Drugs 0.000 title claims abstract description 105
- 239000000203 mixture Substances 0.000 claims abstract description 75
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 claims abstract description 50
- 206010016654 Fibrosis Diseases 0.000 claims abstract description 17
- 230000004761 fibrosis Effects 0.000 claims abstract description 16
- 239000003102 growth factor Substances 0.000 claims description 52
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 34
- 239000000463 material Substances 0.000 claims description 33
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 32
- 229920001184 polypeptide Polymers 0.000 claims description 31
- 108090000190 Thrombin Proteins 0.000 claims description 26
- 239000000126 substance Substances 0.000 claims description 26
- 229960004072 thrombin Drugs 0.000 claims description 26
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 25
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 25
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 210000002744 extracellular matrix Anatomy 0.000 claims description 25
- 239000007789 gas Substances 0.000 claims description 25
- 229920002674 hyaluronan Polymers 0.000 claims description 24
- 229960003160 hyaluronic acid Drugs 0.000 claims description 24
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 23
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 23
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 23
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims description 23
- 239000012190 activator Substances 0.000 claims description 21
- 239000003242 anti bacterial agent Substances 0.000 claims description 17
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 15
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 15
- 108010073651 fibrinmonomer Proteins 0.000 claims description 15
- 239000000178 monomer Substances 0.000 claims description 15
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 14
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 14
- 108010000196 Factor XIIIa Proteins 0.000 claims description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 102000016359 Fibronectins Human genes 0.000 claims description 7
- 108010067306 Fibronectins Proteins 0.000 claims description 7
- 230000003115 biocidal effect Effects 0.000 claims description 7
- 230000000861 pro-apoptotic effect Effects 0.000 claims description 6
- 206010047139 Vasoconstriction Diseases 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 5
- 230000025033 vasoconstriction Effects 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 3
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 3
- 102000002045 Endothelin Human genes 0.000 claims description 3
- 108050009340 Endothelin Proteins 0.000 claims description 3
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 3
- 230000000903 blocking effect Effects 0.000 claims description 3
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 3
- 229960005139 epinephrine Drugs 0.000 claims description 3
- 229960002591 hydroxyproline Drugs 0.000 claims description 3
- 229960002748 norepinephrine Drugs 0.000 claims description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical group C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 3
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 3
- 108090000672 Annexin A5 Proteins 0.000 claims description 2
- 102000004121 Annexin A5 Human genes 0.000 claims description 2
- 108090000397 Caspase 3 Proteins 0.000 claims description 2
- 102100029855 Caspase-3 Human genes 0.000 claims description 2
- 102100026548 Caspase-8 Human genes 0.000 claims description 2
- 108090000538 Caspase-8 Proteins 0.000 claims description 2
- 102100026550 Caspase-9 Human genes 0.000 claims description 2
- 108090000566 Caspase-9 Proteins 0.000 claims description 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims description 2
- 239000002550 vasoactive agent Substances 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 33
- 230000001737 promoting effect Effects 0.000 abstract description 7
- 230000001464 adherent effect Effects 0.000 abstract description 5
- 239000000243 solution Substances 0.000 description 90
- 210000001519 tissue Anatomy 0.000 description 62
- 239000004094 surface-active agent Substances 0.000 description 46
- 239000000499 gel Substances 0.000 description 45
- 210000004027 cell Anatomy 0.000 description 38
- 241001465754 Metazoa Species 0.000 description 37
- 206010014561 Emphysema Diseases 0.000 description 32
- 210000002950 fibroblast Anatomy 0.000 description 32
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 28
- 229920001287 Chondroitin sulfate Polymers 0.000 description 28
- 229940059329 chondroitin sulfate Drugs 0.000 description 28
- 238000006116 polymerization reaction Methods 0.000 description 24
- 238000005259 measurement Methods 0.000 description 23
- 239000003292 glue Substances 0.000 description 21
- 238000007792 addition Methods 0.000 description 20
- 230000006870 function Effects 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 108010035532 Collagen Proteins 0.000 description 16
- 102000008186 Collagen Human genes 0.000 description 16
- 244000309466 calf Species 0.000 description 16
- 229920001436 collagen Polymers 0.000 description 16
- 229920000642 polymer Polymers 0.000 description 15
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 229940088710 antibiotic agent Drugs 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 12
- 239000004365 Protease Substances 0.000 description 12
- 230000012010 growth Effects 0.000 description 12
- 229940055729 papain Drugs 0.000 description 12
- 238000001356 surgical procedure Methods 0.000 description 12
- 108090000526 Papain Proteins 0.000 description 11
- 241001494479 Pecora Species 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- 235000019834 papain Nutrition 0.000 description 11
- 230000003068 static effect Effects 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 210000000038 chest Anatomy 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- 108700025647 major vault Proteins 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 9
- 229910052791 calcium Inorganic materials 0.000 description 9
- 239000011575 calcium Substances 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 230000008021 deposition Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 238000009423 ventilation Methods 0.000 description 8
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 7
- ONPXCLZMBSJLSP-CSMHCCOUSA-N Pro-Hyp Chemical compound C1[C@H](O)C[C@@H](C(O)=O)N1C(=O)[C@H]1NCCC1 ONPXCLZMBSJLSP-CSMHCCOUSA-N 0.000 description 7
- 230000004199 lung function Effects 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 206010003598 Atelectasis Diseases 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 6
- 229930182566 Gentamicin Natural products 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000037390 scarring Effects 0.000 description 6
- 210000003437 trachea Anatomy 0.000 description 6
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 5
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 5
- 102000016611 Proteoglycans Human genes 0.000 description 5
- 108010067787 Proteoglycans Proteins 0.000 description 5
- 229960000723 ampicillin Drugs 0.000 description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 230000009977 dual effect Effects 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 229940066294 lung surfactant Drugs 0.000 description 5
- 239000003580 lung surfactant Substances 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 238000007747 plating Methods 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 238000002203 pretreatment Methods 0.000 description 5
- 238000002271 resection Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229910001424 calcium ion Inorganic materials 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000035605 chemotaxis Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 229960002518 gentamicin Drugs 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- -1 or A. rhodostonza) Proteins 0.000 description 4
- 230000035479 physiological effects, processes and functions Effects 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 108010071289 Factor XIII Proteins 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- 102000019361 Syndecan Human genes 0.000 description 3
- 108050006774 Syndecan Proteins 0.000 description 3
- 102000003790 Thrombin receptors Human genes 0.000 description 3
- 108090000166 Thrombin receptors Proteins 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 230000035565 breathing frequency Effects 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 235000011148 calcium chloride Nutrition 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 229940097043 glucuronic acid Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 230000036573 scar formation Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000000565 sealant Substances 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 102000016284 Aggrecans Human genes 0.000 description 2
- 108010067219 Aggrecans Proteins 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 102000000412 Annexin Human genes 0.000 description 2
- 108050008874 Annexin Proteins 0.000 description 2
- 108010027612 Batroxobin Proteins 0.000 description 2
- 102000004954 Biglycan Human genes 0.000 description 2
- 108090001138 Biglycan Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 0 C*1C(C(*)C(*)C(C(C*(*)O)O)N=O)C1CO Chemical compound C*1C(C(*)C(*)C(C(C*(*)O)O)N=O)C1CO 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 102000011727 Caspases Human genes 0.000 description 2
- 108010076667 Caspases Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 102100033902 Endothelin-1 Human genes 0.000 description 2
- 101800004490 Endothelin-1 Proteins 0.000 description 2
- 101800003778 Fibrinopeptide B Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Chemical group CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Chemical group CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 206010069351 acute lung injury Diseases 0.000 description 2
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 229960002210 batroxobin Drugs 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 210000003123 bronchiole Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001687 destabilization Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 230000007773 growth pattern Effects 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000002570 interstitial cell Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000022275 macrophage chemotaxis Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 230000000379 polymerizing effect Effects 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 210000004879 pulmonary tissue Anatomy 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000003307 slaughter Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000002227 vasoactive effect Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- IWGAAKJQEXBTNA-JPQZOSAESA-N (2r,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(1r,2r,3s,4r,6s)-4,6-diamino-2-[(2s,3r,4s,5r)-4-[(2r,3r,4r,5s,6s)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol;(4r)-4-[[(2s) Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO.S1C([C@@H](N)C(C)CC)=NCC1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C(C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H](C(C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 IWGAAKJQEXBTNA-JPQZOSAESA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- PFKYCGAUNWCWNO-UHFFFAOYSA-N 1,5-diphenyl-1h-tetrazol-1-ium;bromide Chemical compound [Br-].C1=CC=CC=C1[NH+]1C(C=2C=CC=CC=2)=NN=N1 PFKYCGAUNWCWNO-UHFFFAOYSA-N 0.000 description 1
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical group N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010001779 Ancrod Proteins 0.000 description 1
- 206010003130 Arrhythmia supraventricular Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 241000271511 Bothrops atrox Species 0.000 description 1
- 241000392415 Bothrops moojeni Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- SGVUHPSBDNVHKL-UHFFFAOYSA-N CC1CC(C)CCC1 Chemical compound CC1CC(C)CCC1 SGVUHPSBDNVHKL-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 101001051968 Cavia porcellus Fibroblast growth factor 2 Proteins 0.000 description 1
- 108010017573 Ceramide kinase Proteins 0.000 description 1
- 102100036158 Ceramide kinase Human genes 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 102000003965 Endothelin-2 Human genes 0.000 description 1
- 108090000387 Endothelin-2 Proteins 0.000 description 1
- 102100029109 Endothelin-3 Human genes 0.000 description 1
- 108010072844 Endothelin-3 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101800000974 Fibrinopeptide A Proteins 0.000 description 1
- 102400001063 Fibrinopeptide B Human genes 0.000 description 1
- 108090001047 Fibroblast growth factor 10 Proteins 0.000 description 1
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 1
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 1
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100446506 Mus musculus Fgf3 gene Proteins 0.000 description 1
- 101100446513 Mus musculus Fgf4 gene Proteins 0.000 description 1
- ZQQLMECVOXKFJK-NXCSZAMKSA-N N-octadecanoylsphingosine 1-phosphate Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@@H](COP(O)(O)=O)[C@H](O)\C=C\CCCCCCCCCCCCC ZQQLMECVOXKFJK-NXCSZAMKSA-N 0.000 description 1
- 102400000108 N-terminal peptide Human genes 0.000 description 1
- 101800000597 N-terminal peptide Proteins 0.000 description 1
- 108700024605 Nebacetin Proteins 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010035588 Pleural adhesion Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 206010056342 Pulmonary mass Diseases 0.000 description 1
- URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 229930192786 Sisomicin Natural products 0.000 description 1
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 description 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 229940117028 Thrombin receptor agonist Drugs 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 229960004233 ancrod Drugs 0.000 description 1
- 229920001586 anionic polysaccharide Polymers 0.000 description 1
- 150000004836 anionic polysaccharides Chemical class 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 238000013276 bronchoscopy Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 1
- 230000034196 cell chemotaxis Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- ZGOVYTPSWMLYOF-QEADGSHQSA-N chembl1790180 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CC=3C=CC=CC=3)C(=O)N[C@H](C(=O)N[C@H](CCC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)[C@H](C)O)=O)NC(=O)[C@@H]([C@@H](C)O)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZGOVYTPSWMLYOF-QEADGSHQSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- MLFJHYIHIKEBTQ-IYRKOGFYSA-N endothelin 2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSSC[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=3C4=CC=CC=C4NC=3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC1)C1=CNC=N1 MLFJHYIHIKEBTQ-IYRKOGFYSA-N 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 108700004203 eye-derived growth factor Proteins 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- MYRIFIVQGRMHRF-OECXYHNASA-N fibrinopeptide b Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)CNC(=O)[C@@H]1CCC(=O)N1 MYRIFIVQGRMHRF-OECXYHNASA-N 0.000 description 1
- 230000019305 fibroblast migration Effects 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 229940106780 human fibrinogen Drugs 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000013152 interventional procedure Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000004115 mitral valve Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000028550 monocyte chemotaxis Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000009022 nonlinear effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 244000144985 peep Species 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002206 pro-fibrotic effect Effects 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 229960005456 sisomicin Drugs 0.000 description 1
- URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- OXHYRVSBKWIFES-WWSDOYNLSA-N trap-14 peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=CC=C1 OXHYRVSBKWIFES-WWSDOYNLSA-N 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 229940072690 valium Drugs 0.000 description 1
- 230000004865 vascular response Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000009614 wildtype growth Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/00491—Surgical glue applicators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
- A61B17/12104—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in an air passage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12136—Balloons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12181—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices
- A61B17/12186—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices liquid materials adapted to be injected
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
- A61B1/267—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor for the respiratory tract, e.g. laryngoscopes, bronchoscopes
- A61B1/2676—Bronchoscopes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/00491—Surgical glue applicators
- A61B2017/00495—Surgical glue applicators for two-component glue
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Surgical Instruments (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/379,460 | 1999-08-23 | ||
| US09/379,460 US6610043B1 (en) | 1999-08-23 | 1999-08-23 | Tissue volume reduction |
| PCT/US2000/023134 WO2001013908A2 (en) | 1999-08-23 | 2000-08-23 | Tissue volume reduction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2382817A1 CA2382817A1 (en) | 2001-03-01 |
| CA2382817C true CA2382817C (en) | 2013-10-08 |
Family
ID=23497357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2382817A Expired - Fee Related CA2382817C (en) | 1999-08-23 | 2000-08-23 | Use of fibrin or fibrinogen for reducing lung tissue volume |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US6610043B1 (https=) |
| EP (2) | EP1527786A1 (https=) |
| JP (1) | JP2003507130A (https=) |
| CN (1) | CN1236816C (https=) |
| AT (1) | ATE279938T1 (https=) |
| AU (1) | AU783750B2 (https=) |
| CA (1) | CA2382817C (https=) |
| DE (1) | DE60015152T2 (https=) |
| ES (1) | ES2232483T3 (https=) |
| HK (1) | HK1048586B (https=) |
| RU (1) | RU2308967C2 (https=) |
| WO (1) | WO2001013908A2 (https=) |
Families Citing this family (199)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5954766A (en) | 1997-09-16 | 1999-09-21 | Zadno-Azizi; Gholam-Reza | Body fluid flow control device |
| US8016823B2 (en) | 2003-01-18 | 2011-09-13 | Tsunami Medtech, Llc | Medical instrument and method of use |
| US7892229B2 (en) * | 2003-01-18 | 2011-02-22 | Tsunami Medtech, Llc | Medical instruments and techniques for treating pulmonary disorders |
| US7674259B2 (en) * | 2000-12-09 | 2010-03-09 | Tsunami Medtech | Medical instruments and techniques for thermally-mediated therapies |
| US6610043B1 (en) * | 1999-08-23 | 2003-08-26 | Bistech, Inc. | Tissue volume reduction |
| US7654998B1 (en) * | 1999-08-23 | 2010-02-02 | Aeris Therapeutics, Inc. | Tissue volume reduction |
| US8474460B2 (en) | 2000-03-04 | 2013-07-02 | Pulmonx Corporation | Implanted bronchial isolation devices and methods |
| US6679264B1 (en) | 2000-03-04 | 2004-01-20 | Emphasys Medical, Inc. | Methods and devices for use in performing pulmonary procedures |
| US6904909B2 (en) | 2000-03-04 | 2005-06-14 | Emphasys Medical, Inc. | Methods and devices for use in performing pulmonary procedures |
| US8251070B2 (en) | 2000-03-27 | 2012-08-28 | Asthmatx, Inc. | Methods for treating airways |
| US6514290B1 (en) | 2000-03-31 | 2003-02-04 | Broncus Technologies, Inc. | Lung elastic recoil restoring or tissue compressing device and method |
| US6722360B2 (en) | 2000-06-16 | 2004-04-20 | Rajiv Doshi | Methods and devices for improving breathing in patients with pulmonary disease |
| JP2004508140A (ja) * | 2000-09-11 | 2004-03-18 | クロージャー メディカル コーポレイション | 気管支閉塞法および装置 |
| US6527761B1 (en) | 2000-10-27 | 2003-03-04 | Pulmonx, Inc. | Methods and devices for obstructing and aspirating lung tissue segments |
| US7033373B2 (en) | 2000-11-03 | 2006-04-25 | Satiety, Inc. | Method and device for use in minimally invasive placement of space-occupying intragastric devices |
| US7549987B2 (en) * | 2000-12-09 | 2009-06-23 | Tsunami Medtech, Llc | Thermotherapy device |
| US9433457B2 (en) | 2000-12-09 | 2016-09-06 | Tsunami Medtech, Llc | Medical instruments and techniques for thermally-mediated therapies |
| US6623509B2 (en) | 2000-12-14 | 2003-09-23 | Core Medical, Inc. | Apparatus and methods for sealing vascular punctures |
| US6890343B2 (en) | 2000-12-14 | 2005-05-10 | Ensure Medical, Inc. | Plug with detachable guidewire element and methods for use |
| US8083768B2 (en) | 2000-12-14 | 2011-12-27 | Ensure Medical, Inc. | Vascular plug having composite construction |
| US6846319B2 (en) | 2000-12-14 | 2005-01-25 | Core Medical, Inc. | Devices for sealing openings through tissue and apparatus and methods for delivering them |
| US6896692B2 (en) | 2000-12-14 | 2005-05-24 | Ensure Medical, Inc. | Plug with collet and apparatus and method for delivering such plugs |
| US7011094B2 (en) | 2001-03-02 | 2006-03-14 | Emphasys Medical, Inc. | Bronchial flow control devices and methods of use |
| US7798147B2 (en) | 2001-03-02 | 2010-09-21 | Pulmonx Corporation | Bronchial flow control devices with membrane seal |
| US6558400B2 (en) | 2001-05-30 | 2003-05-06 | Satiety, Inc. | Obesity treatment tools and methods |
| US7083629B2 (en) * | 2001-05-30 | 2006-08-01 | Satiety, Inc. | Overtube apparatus for insertion into a body |
| US20030051733A1 (en) | 2001-09-10 | 2003-03-20 | Pulmonx | Method and apparatus for endobronchial diagnosis |
| US7883471B2 (en) | 2001-09-10 | 2011-02-08 | Pulmonx Corporation | Minimally invasive determination of collateral ventilation in lungs |
| US20030050648A1 (en) * | 2001-09-11 | 2003-03-13 | Spiration, Inc. | Removable lung reduction devices, systems, and methods |
| CA2458595C (en) | 2001-10-11 | 2007-12-04 | Peter M. Wilson | Bronchial flow control devices and methods of use |
| US6592594B2 (en) | 2001-10-25 | 2003-07-15 | Spiration, Inc. | Bronchial obstruction device deployment system and method |
| US8444636B2 (en) | 2001-12-07 | 2013-05-21 | Tsunami Medtech, Llc | Medical instrument and method of use |
| US6929637B2 (en) | 2002-02-21 | 2005-08-16 | Spiration, Inc. | Device and method for intra-bronchial provision of a therapeutic agent |
| US7412977B2 (en) * | 2002-03-08 | 2008-08-19 | Emphasys Medical, Inc. | Methods and devices for inducing collapse in lung regions fed by collateral pathways |
| WO2003078579A2 (en) * | 2002-03-11 | 2003-09-25 | Aeris Therapeutics, Inc. | Compositions and methods for treating emphysema |
| US20030216769A1 (en) * | 2002-05-17 | 2003-11-20 | Dillard David H. | Removable anchored lung volume reduction devices and methods |
| US20030181922A1 (en) | 2002-03-20 | 2003-09-25 | Spiration, Inc. | Removable anchored lung volume reduction devices and methods |
| US20030195385A1 (en) * | 2002-04-16 | 2003-10-16 | Spiration, Inc. | Removable anchored lung volume reduction devices and methods |
| US20030212412A1 (en) * | 2002-05-09 | 2003-11-13 | Spiration, Inc. | Intra-bronchial obstructing device that permits mucus transport |
| US7819908B2 (en) * | 2002-06-17 | 2010-10-26 | Aeris Therapeutics, Inc. | Compositions and methods for reducing lung volume |
| WO2003105676A2 (en) * | 2002-06-17 | 2003-12-24 | Bistech, Inc. | Compositions and methods for reducing lung volume |
| US6773440B2 (en) * | 2002-07-02 | 2004-08-10 | Satiety, Inc. | Method and device for use in tissue approximation and fixation |
| WO2004006767A2 (en) * | 2002-07-15 | 2004-01-22 | Spiration, Inc. | Device and method for measuring the diameter of an air passageway |
| US20040059263A1 (en) * | 2002-09-24 | 2004-03-25 | Spiration, Inc. | Device and method for measuring the diameter of an air passageway |
| CA2487405A1 (en) | 2002-07-26 | 2004-02-05 | Emphasys Medical, Inc. | Bronchial flow control devices with membrane seal |
| US6746460B2 (en) * | 2002-08-07 | 2004-06-08 | Satiety, Inc. | Intra-gastric fastening devices |
| US7214233B2 (en) * | 2002-08-30 | 2007-05-08 | Satiety, Inc. | Methods and devices for maintaining a space occupying device in a relatively fixed location within a stomach |
| US7033384B2 (en) | 2002-08-30 | 2006-04-25 | Satiety, Inc. | Stented anchoring of gastric space-occupying devices |
| US7220237B2 (en) * | 2002-10-23 | 2007-05-22 | Satiety, Inc. | Method and device for use in endoscopic organ procedures |
| US7229428B2 (en) * | 2002-10-23 | 2007-06-12 | Satiety, Inc. | Method and device for use in endoscopic organ procedures |
| US6656194B1 (en) * | 2002-11-05 | 2003-12-02 | Satiety, Inc. | Magnetic anchoring devices |
| WO2004047871A2 (en) * | 2002-11-26 | 2004-06-10 | Nobex Corporation | Modified naturetic compounds, conjugates, and uses thereof |
| WO2004049974A2 (en) | 2002-11-27 | 2004-06-17 | Emphasys Medical, Inc. | Delivery method and device for implantable bronchial isolation devices |
| US7814912B2 (en) | 2002-11-27 | 2010-10-19 | Pulmonx Corporation | Delivery methods and devices for implantable bronchial isolation devices |
| US20040210248A1 (en) * | 2003-03-12 | 2004-10-21 | Spiration, Inc. | Apparatus, method and assembly for delivery of intra-bronchial devices |
| US7100616B2 (en) | 2003-04-08 | 2006-09-05 | Spiration, Inc. | Bronchoscopic lung volume reduction method |
| US7175638B2 (en) | 2003-04-16 | 2007-02-13 | Satiety, Inc. | Method and devices for modifying the function of a body organ |
| US8082921B2 (en) * | 2003-04-25 | 2011-12-27 | Anthony David Wondka | Methods, systems and devices for desufflating a lung area |
| US7426929B2 (en) * | 2003-05-20 | 2008-09-23 | Portaero, Inc. | Intra/extra-thoracic collateral ventilation bypass system and method |
| US7533671B2 (en) | 2003-08-08 | 2009-05-19 | Spiration, Inc. | Bronchoscopic repair of air leaks in a lung |
| US7914543B2 (en) * | 2003-10-14 | 2011-03-29 | Satiety, Inc. | Single fold device for tissue fixation |
| US7097650B2 (en) * | 2003-10-14 | 2006-08-29 | Satiety, Inc. | System for tissue approximation and fixation |
| US7361183B2 (en) | 2003-10-17 | 2008-04-22 | Ensure Medical, Inc. | Locator and delivery device and method of use |
| US8852229B2 (en) | 2003-10-17 | 2014-10-07 | Cordis Corporation | Locator and closure device and method of use |
| WO2005065079A2 (en) * | 2003-11-10 | 2005-07-21 | Angiotech International Ag | Medical implants and fibrosis-inducing agents |
| US20050177176A1 (en) * | 2004-02-05 | 2005-08-11 | Craig Gerbi | Single-fold system for tissue approximation and fixation |
| US8828025B2 (en) * | 2004-02-13 | 2014-09-09 | Ethicon Endo-Surgery, Inc. | Methods and devices for reducing hollow organ volume |
| AU2005218318A1 (en) * | 2004-02-27 | 2005-09-15 | Ethicon Endo-Surgery, Inc | Methods and devices for reducing hollow organ volume |
| US8206684B2 (en) | 2004-02-27 | 2012-06-26 | Pulmonx Corporation | Methods and devices for blocking flow through collateral pathways in the lung |
| US8252009B2 (en) * | 2004-03-09 | 2012-08-28 | Ethicon Endo-Surgery, Inc. | Devices and methods for placement of partitions within a hollow body organ |
| US9028511B2 (en) | 2004-03-09 | 2015-05-12 | Ethicon Endo-Surgery, Inc. | Devices and methods for placement of partitions within a hollow body organ |
| US8628547B2 (en) | 2004-03-09 | 2014-01-14 | Ethicon Endo-Surgery, Inc. | Devices and methods for placement of partitions within a hollow body organ |
| US8449560B2 (en) | 2004-03-09 | 2013-05-28 | Satiety, Inc. | Devices and methods for placement of partitions within a hollow body organ |
| CA2561193A1 (en) | 2004-03-26 | 2005-10-20 | Satiety, Inc. | Systems and methods for treating obesity |
| WO2005122870A2 (en) | 2004-06-14 | 2005-12-29 | Pneumrx, Inc. | Lung access device |
| US7468350B2 (en) | 2004-06-16 | 2008-12-23 | Pneumrx, Inc. | Glue composition for lung volume reduction |
| JP2008503254A (ja) * | 2004-06-16 | 2008-02-07 | ヌームアールエックス・インコーポレーテッド | 気管支内肺容量減少システム |
| CN1972706B (zh) | 2004-06-24 | 2012-03-21 | 东菱药品工业株式会社 | 含有去a肽纤维蛋白的恶性肿瘤抑制剂 |
| CA2570261C (en) | 2004-07-08 | 2014-06-10 | Pneumrx, Inc. | Pleural effusion treatment device, method and material |
| US7766891B2 (en) | 2004-07-08 | 2010-08-03 | Pneumrx, Inc. | Lung device with sealing features |
| US20060047291A1 (en) * | 2004-08-20 | 2006-03-02 | Uptake Medical Corporation | Non-foreign occlusion of an airway and lung collapse |
| US8697139B2 (en) | 2004-09-21 | 2014-04-15 | Frank M. Phillips | Method of intervertebral disc treatment using articular chondrocyte cells |
| US20060162731A1 (en) | 2004-11-16 | 2006-07-27 | Pulmonx | Pulmonary occlusal stent delivery catheter, loading system and methods of use |
| WO2006055695A1 (en) | 2004-11-16 | 2006-05-26 | Barry Robert L | Device and method for lung treatment |
| US20060106288A1 (en) | 2004-11-17 | 2006-05-18 | Roth Alex T | Remote tissue retraction device |
| US9211181B2 (en) | 2004-11-19 | 2015-12-15 | Pulmonx Corporation | Implant loading device and system |
| US7771472B2 (en) | 2004-11-19 | 2010-08-10 | Pulmonx Corporation | Bronchial flow control devices and methods of use |
| JP4874259B2 (ja) | 2004-11-23 | 2012-02-15 | ヌームアールエックス・インコーポレーテッド | 標的部位にアクセスするための操縦可能な装置 |
| CN101223187A (zh) * | 2004-11-24 | 2008-07-16 | 萨拉普托斯股份公司 | 用作双重胱天蛋白酶-2/-6抑制剂的新肽及其生物学应用 |
| EP1824544B1 (en) | 2004-12-08 | 2013-06-05 | Ventus Medical, Inc. | Respiratory devices and methods of use |
| US9833354B2 (en) | 2004-12-08 | 2017-12-05 | Theravent, Inc. | Nasal respiratory devices |
| US10610228B2 (en) | 2004-12-08 | 2020-04-07 | Theravent, Inc. | Passive nasal peep devices |
| US8611983B2 (en) * | 2005-01-18 | 2013-12-17 | Philips Electronics Ltd | Method and apparatus for guiding an instrument to a target in the lung |
| US20080228137A1 (en) | 2007-03-12 | 2008-09-18 | Pulmonx | Methods and devices for passive residual lung volume reduction and functional lung volume expansion |
| US11883029B2 (en) | 2005-01-20 | 2024-01-30 | Pulmonx Corporation | Methods and devices for passive residual lung volume reduction and functional lung volume expansion |
| US8496006B2 (en) | 2005-01-20 | 2013-07-30 | Pulmonx Corporation | Methods and devices for passive residual lung volume reduction and functional lung volume expansion |
| US8876791B2 (en) | 2005-02-25 | 2014-11-04 | Pulmonx Corporation | Collateral pathway treatment using agent entrained by aspiration flow current |
| US8088144B2 (en) | 2005-05-04 | 2012-01-03 | Ensure Medical, Inc. | Locator and closure device and method of use |
| US8926654B2 (en) | 2005-05-04 | 2015-01-06 | Cordis Corporation | Locator and closure device and method of use |
| FR2887883B1 (fr) | 2005-06-29 | 2007-08-31 | Lab Francais Du Fractionnement | Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines |
| US20070032785A1 (en) | 2005-08-03 | 2007-02-08 | Jennifer Diederich | Tissue evacuation device |
| EP3492008B1 (en) | 2005-09-13 | 2021-06-02 | Veran Medical Technologies, Inc. | Apparatus and method for image guided accuracy verification |
| US20070066881A1 (en) | 2005-09-13 | 2007-03-22 | Edwards Jerome R | Apparatus and method for image guided accuracy verification |
| CN101466408A (zh) * | 2005-11-02 | 2009-06-24 | 艾里斯治疗公司 | 聚阳离子-聚阴离子络合物、组合物及其使用方法 |
| US8523782B2 (en) | 2005-12-07 | 2013-09-03 | Pulmonx Corporation | Minimally invasive determination of collateral ventilation in lungs |
| EP1986568B1 (en) | 2006-02-03 | 2017-04-05 | Covidien LP | Methods and devices for restoring blood flow within blocked vasculature |
| US8888800B2 (en) | 2006-03-13 | 2014-11-18 | Pneumrx, Inc. | Lung volume reduction devices, methods, and systems |
| US8157837B2 (en) | 2006-03-13 | 2012-04-17 | Pneumrx, Inc. | Minimally invasive lung volume reduction device and method |
| US9402633B2 (en) | 2006-03-13 | 2016-08-02 | Pneumrx, Inc. | Torque alleviating intra-airway lung volume reduction compressive implant structures |
| US8721734B2 (en) | 2009-05-18 | 2014-05-13 | Pneumrx, Inc. | Cross-sectional modification during deployment of an elongate lung volume reduction device |
| US9801637B2 (en) | 2006-03-13 | 2017-10-31 | Pneumrx, Inc. | Genetically-associated chronic obstructive pulmonary disease treatment |
| US7691151B2 (en) * | 2006-03-31 | 2010-04-06 | Spiration, Inc. | Articulable Anchor |
| WO2007139890A2 (en) | 2006-05-23 | 2007-12-06 | Ventus Medical, Inc. | Nasal respiratory devices |
| GB0610171D0 (en) | 2006-05-23 | 2006-06-28 | Robitaille Jean Pierre | Valved nasal canula |
| US7506649B2 (en) | 2006-06-07 | 2009-03-24 | Ventus Medical, Inc. | Nasal devices |
| WO2007146189A2 (en) | 2006-06-07 | 2007-12-21 | Ventus Medical, Inc. | Nasal respiratory devices for positive end-expiratory pressure |
| WO2008027293A2 (en) * | 2006-08-25 | 2008-03-06 | Emphasys Medical, Inc. | Bronchial isolation devices for placement in short lumens |
| WO2008039827A2 (en) * | 2006-09-26 | 2008-04-03 | Aeris Therapeutics, Inc. | Polymer systems for lung volume reduction therapy |
| US8585645B2 (en) | 2006-11-13 | 2013-11-19 | Uptake Medical Corp. | Treatment with high temperature vapor |
| US7993323B2 (en) | 2006-11-13 | 2011-08-09 | Uptake Medical Corp. | High pressure and high temperature vapor catheters and systems |
| WO2008061250A2 (en) | 2006-11-16 | 2008-05-22 | Ventus Medical, Inc. | Adjustable nasal devices |
| US20080132757A1 (en) * | 2006-12-01 | 2008-06-05 | General Electric Company | System and Method for Performing Minimally Invasive Surgery Using a Multi-Channel Catheter |
| BRPI0718328A2 (pt) | 2006-12-15 | 2011-10-11 | Lifebond Ltd | composição, curativo hemostático e dispositivo médico para a inserção em um corpo de um ser humano ou de um mamìfero inferior |
| US8911750B2 (en) * | 2007-04-03 | 2014-12-16 | Larry W. Tsai | Lung volume reduction therapy using crosslinked biopolymers |
| WO2009009398A1 (en) | 2007-07-06 | 2009-01-15 | Tsunami Medtech, Llc | Medical system and method of use |
| US8197470B2 (en) | 2007-08-23 | 2012-06-12 | Aegea Medical, Inc. | Uterine therapy device and method |
| US8043301B2 (en) | 2007-10-12 | 2011-10-25 | Spiration, Inc. | Valve loader method, system, and apparatus |
| JP5570993B2 (ja) | 2007-10-12 | 2014-08-13 | スピレーション インコーポレイテッド | 弁装填具の方法、システム、および装置 |
| ES2456965T3 (es) * | 2007-10-22 | 2014-04-24 | Uptake Medical Corp. | Determinación de los parámetros del tratamiento de vapor y de administración específicos del paciente |
| US8322335B2 (en) | 2007-10-22 | 2012-12-04 | Uptake Medical Corp. | Determining patient-specific vapor treatment and delivery parameters |
| US8020700B2 (en) | 2007-12-05 | 2011-09-20 | Ventus Medical, Inc. | Packaging and dispensing nasal devices |
| US9924992B2 (en) | 2008-02-20 | 2018-03-27 | Tsunami Medtech, Llc | Medical system and method of use |
| WO2009117012A1 (en) | 2008-03-17 | 2009-09-24 | Ventus Medical, Inc. | Adhesive nasal respiratory devices |
| US8557773B2 (en) * | 2008-05-02 | 2013-10-15 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Treatment of bleeding with low half-life fibrinogen |
| US8721632B2 (en) | 2008-09-09 | 2014-05-13 | Tsunami Medtech, Llc | Methods for delivering energy into a target tissue of a body |
| US8579888B2 (en) | 2008-06-17 | 2013-11-12 | Tsunami Medtech, Llc | Medical probes for the treatment of blood vessels |
| EP2487206A3 (en) * | 2008-06-18 | 2012-11-28 | Lifebond Ltd | Cross-linkable gelatin-based compositions |
| WO2009153748A2 (en) * | 2008-06-18 | 2009-12-23 | Lifebond Ltd | Methods and devices for use with sealants |
| US9173669B2 (en) | 2008-09-12 | 2015-11-03 | Pneumrx, Inc. | Enhanced efficacy lung volume reduction devices, methods, and systems |
| US10064697B2 (en) | 2008-10-06 | 2018-09-04 | Santa Anna Tech Llc | Vapor based ablation system for treating various indications |
| US9561068B2 (en) | 2008-10-06 | 2017-02-07 | Virender K. Sharma | Method and apparatus for tissue ablation |
| US9561066B2 (en) | 2008-10-06 | 2017-02-07 | Virender K. Sharma | Method and apparatus for tissue ablation |
| US10695126B2 (en) | 2008-10-06 | 2020-06-30 | Santa Anna Tech Llc | Catheter with a double balloon structure to generate and apply a heated ablative zone to tissue |
| CN104739502B (zh) | 2008-10-06 | 2018-01-19 | 维兰德·K·沙马 | 用于组织消融的方法和装置 |
| US8444635B2 (en) * | 2008-11-19 | 2013-05-21 | Samuel Victor Lichtenstein | Methods for selectively heating tissue |
| US11284931B2 (en) | 2009-02-03 | 2022-03-29 | Tsunami Medtech, Llc | Medical systems and methods for ablating and absorbing tissue |
| WO2010102307A1 (en) | 2009-03-06 | 2010-09-10 | Lazarus Effect, Inc. | Retrieval systems and methods for use thereof |
| US8900223B2 (en) | 2009-11-06 | 2014-12-02 | Tsunami Medtech, Llc | Tissue ablation systems and methods of use |
| WO2011077388A1 (en) | 2009-12-22 | 2011-06-30 | Lifebond Ltd | Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices |
| US9161801B2 (en) | 2009-12-30 | 2015-10-20 | Tsunami Medtech, Llc | Medical system and method of use |
| US8875711B2 (en) | 2010-05-27 | 2014-11-04 | Theravent, Inc. | Layered nasal respiratory devices |
| EP2397074B1 (en) | 2010-06-19 | 2012-10-24 | M Stenqvist AB | A system and computer readable medium for determination of transpulmonary pressure in a patient connected to a breathing apparatus |
| US9592008B2 (en) | 2010-07-01 | 2017-03-14 | Pulmonx Corporation | Devices and systems for lung treatment |
| US8808194B2 (en) | 2010-07-01 | 2014-08-19 | Pulmonx Corporation | Methods and systems for endobronchial diagnostics |
| US8961544B2 (en) | 2010-08-05 | 2015-02-24 | Lifebond Ltd. | Dry composition wound dressings and adhesives comprising gelatin and transglutaminase in a cross-linked matrix |
| US9943353B2 (en) | 2013-03-15 | 2018-04-17 | Tsunami Medtech, Llc | Medical system and method of use |
| JP2012045358A (ja) * | 2010-08-25 | 2012-03-08 | Terumo Corp | 肺気腫の治療剤 |
| US9743974B2 (en) | 2010-11-09 | 2017-08-29 | Aegea Medical Inc. | Positioning method and apparatus for delivering vapor to the uterus |
| US8795241B2 (en) | 2011-05-13 | 2014-08-05 | Spiration, Inc. | Deployment catheter |
| EP2760390B1 (en) | 2011-09-29 | 2019-06-12 | Trudell Medical International | Nasal insert |
| CN104135960B (zh) | 2011-10-07 | 2017-06-06 | 埃杰亚医疗公司 | 一种子宫治疗装置 |
| EP2816966B1 (en) | 2012-02-22 | 2023-10-25 | Veran Medical Technologies, Inc. | Steerable surgical catheter comprising a biopsy device at the distal end portion thereof |
| JP2015097547A (ja) * | 2012-03-09 | 2015-05-28 | テルモ株式会社 | バルーンカテーテル |
| JP2013202201A (ja) | 2012-03-28 | 2013-10-07 | Terumo Corp | 医療用長尺体 |
| EP2945556A4 (en) | 2013-01-17 | 2016-08-31 | Virender K Sharma | METHOD AND DEVICE FOR TISSUE REMOVAL |
| US9827271B2 (en) | 2013-03-15 | 2017-11-28 | Cook Biotech Incorporated | Methods and devices for lung volume reduction with extracellular matrix material |
| WO2015021408A1 (en) | 2013-08-09 | 2015-02-12 | Boston Scientific Scimed, Inc. | Devices for treating a lung |
| US9782211B2 (en) | 2013-10-01 | 2017-10-10 | Uptake Medical Technology Inc. | Preferential volume reduction of diseased segments of a heterogeneous lobe |
| WO2015061790A2 (en) * | 2013-10-25 | 2015-04-30 | Pneumrx, Inc. | Genetically-associated chronic obstructive pulmonary disease treatment |
| US20150305612A1 (en) | 2014-04-23 | 2015-10-29 | Mark Hunter | Apparatuses and methods for registering a real-time image feed from an imaging device to a steerable catheter |
| US20150305650A1 (en) | 2014-04-23 | 2015-10-29 | Mark Hunter | Apparatuses and methods for endobronchial navigation to and confirmation of the location of a target tissue and percutaneous interception of the target tissue |
| ES2942296T3 (es) | 2014-05-22 | 2023-05-31 | Aegea Medical Inc | Método de prueba de integridad y aparato para administrar vapor al útero |
| CN106794030B (zh) | 2014-05-22 | 2019-09-03 | 埃杰亚医疗公司 | 用于执行子宫内膜消融术的系统和方法 |
| US10390838B1 (en) | 2014-08-20 | 2019-08-27 | Pneumrx, Inc. | Tuned strength chronic obstructive pulmonary disease treatment |
| US10485604B2 (en) | 2014-12-02 | 2019-11-26 | Uptake Medical Technology Inc. | Vapor treatment of lung nodules and tumors |
| US10531906B2 (en) | 2015-02-02 | 2020-01-14 | Uptake Medical Technology Inc. | Medical vapor generator |
| US10456560B2 (en) | 2015-02-11 | 2019-10-29 | Covidien Lp | Expandable tip medical devices and methods |
| US10624733B2 (en) | 2015-03-24 | 2020-04-21 | Spiration, Inc. | Airway stent |
| WO2017011668A1 (en) * | 2015-07-14 | 2017-01-19 | Boston Scientific Scimed, Inc. | Gel delivery catheters, systems, and methods |
| ES2815423T3 (es) | 2016-02-05 | 2021-03-30 | Pulmonx Corp | Procedimientos, sistemas y dispositivos para analizar datos de imágenes pulmonares |
| CN114983553A (zh) | 2016-02-19 | 2022-09-02 | 埃杰亚医疗公司 | 用于确定体腔的完整性的方法和设备 |
| US10980737B1 (en) | 2016-03-08 | 2021-04-20 | Samuel Victor Lichtenstein | System for treating unwanted tissue using heat and heat activated drugs |
| US12364537B2 (en) | 2016-05-02 | 2025-07-22 | Santa Anna Tech Llc | Catheter with a double balloon structure to generate and apply a heated ablative zone to tissue |
| US11331140B2 (en) | 2016-05-19 | 2022-05-17 | Aqua Heart, Inc. | Heated vapor ablation systems and methods for treating cardiac conditions |
| CN106512088B (zh) * | 2016-12-09 | 2019-02-26 | 中国医学科学院生物医学工程研究所 | 磷脂-糖胺聚糖仿生细胞外基质纳米膜及其制备方法与应用 |
| CN108272538B (zh) * | 2016-12-30 | 2020-06-12 | 先健科技(深圳)有限公司 | 肺减容弹性植入体及肺减容器械 |
| CN110545872B (zh) | 2017-02-22 | 2022-11-08 | 皇家飞利浦有限公司 | 机械通气的自动peep选择 |
| US11129673B2 (en) | 2017-05-05 | 2021-09-28 | Uptake Medical Technology Inc. | Extra-airway vapor ablation for treating airway constriction in patients with asthma and COPD |
| US11344364B2 (en) | 2017-09-07 | 2022-05-31 | Uptake Medical Technology Inc. | Screening method for a target nerve to ablate for the treatment of inflammatory lung disease |
| US11350988B2 (en) | 2017-09-11 | 2022-06-07 | Uptake Medical Technology Inc. | Bronchoscopic multimodality lung tumor treatment |
| USD845467S1 (en) | 2017-09-17 | 2019-04-09 | Uptake Medical Technology Inc. | Hand-piece for medical ablation catheter |
| US11419658B2 (en) | 2017-11-06 | 2022-08-23 | Uptake Medical Technology Inc. | Method for treating emphysema with condensable thermal vapor |
| US11490946B2 (en) | 2017-12-13 | 2022-11-08 | Uptake Medical Technology Inc. | Vapor ablation handpiece |
| WO2019232432A1 (en) | 2018-06-01 | 2019-12-05 | Santa Anna Tech Llc | Multi-stage vapor-based ablation treatment methods and vapor generation and delivery systems |
| US20240398462A1 (en) | 2018-06-01 | 2024-12-05 | Aqua Medical, Inc. | Duodenal Ablation with Improved Depth and Consistency of Ablation |
| US11998654B2 (en) | 2018-07-12 | 2024-06-04 | Bard Shannon Limited | Securing implants and medical devices |
| US11653927B2 (en) | 2019-02-18 | 2023-05-23 | Uptake Medical Technology Inc. | Vapor ablation treatment of obstructive lung disease |
| CN114126694B (zh) * | 2019-12-03 | 2024-08-23 | 深圳迈瑞生物医疗电子股份有限公司 | 一种患者通气监测装置及其通气监测方法 |
| CN112843436A (zh) * | 2020-02-16 | 2021-05-28 | 东莞天天向上医疗科技有限公司 | 一种体内肺膜氧合多功能球囊扩张导管及使用方法 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3089815A (en) | 1951-10-11 | 1963-05-14 | Lieb Hans | Injectable pharmaceutical preparation, and a method of making same |
| US4013507A (en) | 1973-09-18 | 1977-03-22 | California Institute Of Technology | Ionene polymers for selectively inhibiting the vitro growth of malignant cells |
| US4393041A (en) | 1980-04-25 | 1983-07-12 | International Minerals & Chemical Corp. | Fibrin binder/carrier for active biochemical agents |
| US4442655A (en) | 1981-06-25 | 1984-04-17 | Serapharm Michael Stroetmann | Fibrinogen-containing dry preparation, manufacture and use thereof |
| EP0110498B2 (en) | 1982-11-22 | 1991-09-18 | Teijin Limited | Artificial lung surfactant and remedy for respiratory distress syndrome containing it as active principle |
| AT379311B (de) * | 1984-03-29 | 1985-12-27 | Immuno Ag | Vorrichtung zur applikation eines gewebeklebstoffes |
| US4619913A (en) | 1984-05-29 | 1986-10-28 | Matrix Pharmaceuticals, Inc. | Treatments employing drug-containing matrices for introduction into cellular lesion areas |
| US4719282A (en) | 1986-04-22 | 1988-01-12 | Miranol Inc. | Polycationic block copolymer |
| EP0303756A3 (en) | 1987-08-17 | 1991-02-20 | B. Braun Medical Inc. | Thermodilution and pressure transducer balloon catheter |
| US4886496A (en) | 1988-02-04 | 1989-12-12 | Conoscenti Craig S | Bronchoscopic balloon tipped catheter and method of making the same |
| US5290552A (en) | 1988-05-02 | 1994-03-01 | Matrix Pharmaceutical, Inc./Project Hear | Surgical adhesive material |
| US5654267A (en) * | 1988-12-20 | 1997-08-05 | La Jolla Cancer Research Center | Cooperative combinations of ligands contained within a matrix |
| WO1992007819A1 (fr) * | 1990-10-25 | 1992-05-14 | Yamanouchi Pharmaceutical Co., Ltd. | Derive de tri(alcoxy inferieur)benzene |
| US6117425A (en) * | 1990-11-27 | 2000-09-12 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, method of their production and use |
| EP1142581A3 (en) | 1990-11-27 | 2002-09-11 | American National Red Cross | Tissue sealant and growth factor containing compositions that promote accelerated wound healing |
| WO1992013547A1 (en) | 1991-02-07 | 1992-08-20 | Alexander Mellon Eaton | Drug delivery composition and method of using the same |
| US5690675A (en) * | 1991-02-13 | 1997-11-25 | Fusion Medical Technologies, Inc. | Methods for sealing of staples and other fasteners in tissue |
| US5851828A (en) | 1991-03-07 | 1998-12-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
| US6399569B1 (en) * | 1991-03-11 | 2002-06-04 | Curis, Inc. | Morphogen treatments for limiting proliferation of epithelial cells |
| US5714470A (en) | 1991-08-22 | 1998-02-03 | Merrell Pharmaceuticals, Inc. | Orally-active elastase inhibitors |
| IL107120A (en) | 1992-09-29 | 1997-09-30 | Boehringer Ingelheim Int | Atomising nozzle and filter and spray generating device |
| CN1091315A (zh) | 1992-10-08 | 1994-08-31 | E·R·斯奎布父子公司 | 血纤维蛋白封闭剂组合物及其使用方法 |
| US5423312A (en) | 1992-12-18 | 1995-06-13 | Schott Fiber Optics, Inc. | Rigid endoscope having modified high refractive index tunnel rod for image transmission and method of manufacture thereof |
| US5395923A (en) * | 1993-02-23 | 1995-03-07 | Haemacure-Biotech, Inc. | Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out" |
| RU2092108C1 (ru) * | 1993-03-15 | 1997-10-10 | Владимир Николаевич Вечерко | Способ лечения гнойной деструкции легких и устройство для его осуществления |
| GB9311614D0 (en) | 1993-06-04 | 1993-07-21 | Aid Medic Ltd | Nebulizer |
| US5437292A (en) | 1993-11-19 | 1995-08-01 | Bioseal, Llc | Method for sealing blood vessel puncture sites |
| EP0748215B1 (en) | 1994-02-17 | 2003-05-28 | New York Blood Center, Inc. | Biologic bioadhesive compositions containing fibrin glue and liposomes, methods of preparation and use |
| US5836905A (en) * | 1994-06-20 | 1998-11-17 | Lemelson; Jerome H. | Apparatus and methods for gene therapy |
| DE4423178A1 (de) | 1994-07-01 | 1996-01-04 | Schubert Werner | Vorrichtung für die minimalchirurgische Laparoskopie |
| US5583114A (en) | 1994-07-27 | 1996-12-10 | Minnesota Mining And Manufacturing Company | Adhesive sealant composition |
| EP1486226A3 (en) | 1994-10-28 | 2005-11-09 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| US6001814A (en) | 1994-11-21 | 1999-12-14 | Cortech Inc. | Serine protease inhibitors |
| US5733545A (en) | 1995-03-03 | 1998-03-31 | Quantic Biomedical Partners | Platelet glue wound sealant |
| EP0861048A4 (en) | 1995-07-03 | 2000-05-17 | Dirk A Frater | SYSTEM FOR FASTENING SUPPORT MATERIAL ON TISSUE CLASP DEVICES |
| US5660175A (en) * | 1995-08-21 | 1997-08-26 | Dayal; Bimal | Endotracheal device |
| US5814022A (en) * | 1996-02-06 | 1998-09-29 | Plasmaseal Llc | Method and apparatus for applying tissue sealant |
| GB9602969D0 (en) | 1996-02-13 | 1996-04-10 | The Technology Partnership Plc | Liquid supply apparatus |
| DE69734557T2 (de) | 1996-03-15 | 2006-07-27 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Sprühvorrichtung zum aufbringen von gewebeklebstoff |
| US5728132A (en) | 1996-04-08 | 1998-03-17 | Tricardia, L.L.C. | Self-sealing vascular access device |
| CA2254898A1 (en) | 1996-05-14 | 1997-11-20 | C.R. Bard, Inc. | Methods and products for sealing a fluid leak in a tissue |
| SE9602226D0 (sv) | 1996-06-05 | 1996-06-05 | Astra Ab | Biocompatible glue |
| US5780440A (en) | 1996-06-17 | 1998-07-14 | Protease Sciences Inc. | Treatment of pulmonary disease with protease inhibitors |
| IT1284108B1 (it) | 1996-07-04 | 1998-05-08 | Carlo Rebuffat | Presidio chirurgico per il trattamento dell'enfisema polmonare |
| US5782748A (en) | 1996-07-10 | 1998-07-21 | Symbiosis Corporation | Endoscopic surgical instruments having detachable proximal and distal portions |
| US5728751A (en) | 1996-11-25 | 1998-03-17 | Meadox Medicals, Inc. | Bonding bio-active materials to substrate surfaces |
| US20030114384A1 (en) | 2001-11-28 | 2003-06-19 | Podolsky Daniel K. | Methods and compositions for treating lesions of the respiratory epithelium |
| CA2308462C (en) | 1997-11-17 | 2009-02-24 | Haemacure Corporation | Fibrin sealants or adhesives comprising a hyaluronic acid derivative material |
| US6174323B1 (en) * | 1998-06-05 | 2001-01-16 | Broncus Technologies, Inc. | Method and assembly for lung volume reduction |
| US6599311B1 (en) | 1998-06-05 | 2003-07-29 | Broncus Technologies, Inc. | Method and assembly for lung volume reduction |
| US5883084A (en) | 1998-06-08 | 1999-03-16 | Clarion Pharmaceuticals Inc. | Treatment of respiratory diseases utilizing α-tocopheryl-phosphocholine |
| US6333194B1 (en) | 1999-01-19 | 2001-12-25 | The Children's Hospital Of Philadelphia | Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof |
| US6287290B1 (en) | 1999-07-02 | 2001-09-11 | Pulmonx | Methods, systems, and kits for lung volume reduction |
| IL147269A0 (en) * | 1999-07-02 | 2002-08-14 | Genentech Inc | FVIIa ANTAGONISTS |
| US6440706B1 (en) | 1999-08-02 | 2002-08-27 | Johns Hopkins University | Digital amplification |
| US6610043B1 (en) * | 1999-08-23 | 2003-08-26 | Bistech, Inc. | Tissue volume reduction |
| US6293951B1 (en) | 1999-08-24 | 2001-09-25 | Spiration, Inc. | Lung reduction device, system, and method |
| AU7985700A (en) | 1999-10-14 | 2001-04-23 | Trustees Of Boston University | Variable peak pressure ventilation method and system |
| US6743259B2 (en) | 2001-08-03 | 2004-06-01 | Core Medical, Inc. | Lung assist apparatus and methods for use |
| US6645205B2 (en) | 2001-08-15 | 2003-11-11 | Core Medical, Inc. | Apparatus and methods for reducing lung volume |
| US6592594B2 (en) | 2001-10-25 | 2003-07-15 | Spiration, Inc. | Bronchial obstruction device deployment system and method |
| US20030099601A1 (en) | 2001-11-27 | 2003-05-29 | Gordon Marc S. | Inhalation lung surfactant therapy |
| WO2003078579A2 (en) | 2002-03-11 | 2003-09-25 | Aeris Therapeutics, Inc. | Compositions and methods for treating emphysema |
| WO2003105676A2 (en) | 2002-06-17 | 2003-12-24 | Bistech, Inc. | Compositions and methods for reducing lung volume |
| US6886558B2 (en) | 2002-08-28 | 2005-05-03 | Cordis Corporation | Collateral ventilation bypass trap system |
-
1999
- 1999-08-23 US US09/379,460 patent/US6610043B1/en not_active Expired - Lifetime
-
2000
- 2000-08-23 AU AU67993/00A patent/AU783750B2/en not_active Expired
- 2000-08-23 WO PCT/US2000/023134 patent/WO2001013908A2/en not_active Ceased
- 2000-08-23 CN CNB008120412A patent/CN1236816C/zh not_active Expired - Lifetime
- 2000-08-23 AT AT00955858T patent/ATE279938T1/de active
- 2000-08-23 CA CA2382817A patent/CA2382817C/en not_active Expired - Fee Related
- 2000-08-23 HK HK02108456.8A patent/HK1048586B/en not_active IP Right Cessation
- 2000-08-23 ES ES00955858T patent/ES2232483T3/es not_active Expired - Lifetime
- 2000-08-23 DE DE60015152T patent/DE60015152T2/de not_active Expired - Lifetime
- 2000-08-23 RU RU2002107319/14A patent/RU2308967C2/ru not_active IP Right Cessation
- 2000-08-23 JP JP2001518046A patent/JP2003507130A/ja active Pending
- 2000-08-23 EP EP04024842A patent/EP1527786A1/en not_active Withdrawn
- 2000-08-23 EP EP00955858A patent/EP1206276B1/en not_active Expired - Lifetime
-
2001
- 2001-04-20 US US09/839,253 patent/US6682520B2/en not_active Expired - Lifetime
-
2003
- 2003-08-26 US US10/649,232 patent/US7654999B2/en not_active Expired - Fee Related
-
2004
- 2004-12-11 US US11/009,379 patent/US7300428B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2382817A1 (en) | 2001-03-01 |
| US6682520B2 (en) | 2004-01-27 |
| US6610043B1 (en) | 2003-08-26 |
| EP1206276A2 (en) | 2002-05-22 |
| DE60015152T2 (de) | 2006-02-02 |
| US7300428B2 (en) | 2007-11-27 |
| CN1236816C (zh) | 2006-01-18 |
| EP1527786A1 (en) | 2005-05-04 |
| JP2003507130A (ja) | 2003-02-25 |
| WO2001013908A3 (en) | 2002-01-24 |
| US7654999B2 (en) | 2010-02-02 |
| RU2308967C2 (ru) | 2007-10-27 |
| ATE279938T1 (de) | 2004-11-15 |
| US20040038868A1 (en) | 2004-02-26 |
| WO2001013908A2 (en) | 2001-03-01 |
| WO2001013908A9 (en) | 2002-06-27 |
| US20050239685A1 (en) | 2005-10-27 |
| US20010051799A1 (en) | 2001-12-13 |
| AU783750B2 (en) | 2005-12-01 |
| HK1048586A1 (en) | 2003-04-11 |
| DE60015152D1 (de) | 2004-11-25 |
| EP1206276B1 (en) | 2004-10-20 |
| HK1048586B (en) | 2005-06-03 |
| ES2232483T3 (es) | 2005-06-01 |
| CN1373670A (zh) | 2002-10-09 |
| AU6799300A (en) | 2001-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2382817C (en) | Use of fibrin or fibrinogen for reducing lung tissue volume | |
| US7819908B2 (en) | Compositions and methods for reducing lung volume | |
| US7654998B1 (en) | Tissue volume reduction | |
| CA2530042C (en) | Compositions and methods for reducing lung volume | |
| EP2146733B1 (en) | Treatment of leaky or damaged tight junctions and enhancing extracellular matrix | |
| US20050118156A1 (en) | Storage-stable fibrin sealant | |
| RU2556960C2 (ru) | Способ обеспечения улучшенного уплотнения с помощью фибрина | |
| US8461115B2 (en) | Methods for local treatment with factor VII | |
| AU2006200887A1 (en) | Tissue volume reduction | |
| EP4537859A1 (en) | Fibrin gel and method for obtaining same | |
| RU2270016C2 (ru) | Гемостатический клей | |
| Kram et al. | Use of concentrated fibrinogen in experimental tracheal repair | |
| Talyshinskii et al. | RADA16 as a novel hemostatic and regenerative agent in urology: European Association of Urology endourology up-to-date overview | |
| HK1140431A (en) | Treatment of leaky or damaged tight junctions and enhancing extracellular matrix | |
| HK1140431B (en) | Treatment of leaky or damaged tight junctions and enhancing extracellular matrix |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20150824 |